Motilal Oswal Financial Services has reiterated its BUY recommendation for Sun Pharma, assigning a 12-month target price of Rs 1,960, with the stock currently trading at Rs 1,690.

India’s biotechnology industry, one of the fastest-expanding sectors globally, is blazing new trails across healthcare, pharmaceuticals, and sustainability.

Motilal Oswal Financial Services has reiterated its BUY call on Laurus Labs, highlighting a robust earnings trajectory and strategic capital deployment in CDMO and generics segments.

Costco’s decision to introduce discounted pricing on Ozempic and Wegovy marks a pivotal moment in both the U.S.

Motilal Oswal Financial Services has suggested BUY recommendation for Sun Pharmaceutical, targeting a 12-month price of Rs 1,960.

Prabhudas Lilladher has initiated a BUY call on Ajanta Pharma, urging investors to seize this opportunity based on the company’s robust branded generics (BGx) franchise, promising financial perform